AOC 1044 Exon 44 Skipping Therapy for Duchenne Muscular Dystrophy: EXPLORE44 Clinical Trial

If on corticosteroids, stable dose for 30 days before screening and throughout the study.

• Rollover Participants:
• Satisfactorily completed AOC 1044-CS1 (EXPLORE44) as determined by the Investigator and Sponsor
• No significant tolerability issues with AOC 1044
• De novo Participants:
• Aged 7 to 27 years, inclusive, at the time of informed consent
• Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years
• Confirmation of DMD gene mutation amenable to exon 44 skipping
• PUL 2.0 entry item A ≥3

• Rollover Participants:
• Presence of any new condition or worsening of existing condition that could affect a participant's safety or ability to comply with study procedures
• De novo Participants:
• Serum hemoglobin < lower limit of normal
• Uncontrolled hypertension or diabetes
• Prior treatment with any cell or gene therapy
• Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent
• Recently treated with an investigational drug
• History of multiple drug allergies